Leneva Allograft Adipose Matrix is comprised of adipose tissue which is intended for the replacement of damaged or inadequate integumental adipose tissue matrix in areas of the body where native fat would exist. Leneva Allograft Adipose Matrix may also be used for the reinforcement or supplemental support in underlying adipose tissue matrix as the result of damage or naturally occurring defects. The process utilized preserves the extracellular matrix of the allograft adipose. The resulting allograft serves as a framework to support the cellular repopulation and vascularization at the surgical site.

As an HCT/P Leneva does not have specific indications. It is intended for homologous use and should be used for the replacement or augmentation of damaged or inadequate integumental adipose tissue.

The safety and remodeling over time of Leneva in human patients was shown in a clinical study, where no severe adverse events were reported and injected Leneva was completely remodeled into native fat by 6 months.3 This and other relevant published peer-reviewed clinical articles, as well as clinical case summaries, can be provided by request to by your Wound Care Consultant.

Leneva can be used anywhere on the body where adipose tissue naturally occurs.

Leneva is regulated as a human cell/tissue product (H/CTP) under 21 CFR Part 1271 and Section 361 of the Public Health Services Act. FDA registration listing can be found on the company website mtfbiologics.org or can be provided upon request.

Offloading is recommended after injecting Leneva. Patients are commonly offloaded for two to four weeks. Use preferred offloading method based on your clinical discretion.